The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment of Femoropopliteal TASC C&D Lesions (ZILVERPASS).
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral artery restenosis; Peripheral vascular disorders
- Focus Therapeutic Use
- Acronyms ZILVERPASS
- 11 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Sep 2017.
- 11 Jan 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
- 05 Aug 2014 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov record.